Revvity, Inc. (RVTY)
Automate Your Wheel Strategy on RVTY
With Tiblio's Option Bot, you can configure your own wheel strategy including RVTY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RVTY
- Rev/Share 23.0559
- Book/Share 63.5702
- PB 1.4508
- Debt/Equity 0.4354
- CurrentRatio 3.576
- ROIC 0.0284
- MktCap 10871150100.0
- FreeCF/Share 4.3626
- PFCF 20.7423
- PE 38.6598
- Debt/Assets 0.269
- DivYield 0.003
- ROE 0.0369
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | RVTY | UBS | Neutral | Buy | -- | $115 | May 1, 2025 |
| Downgrade | RVTY | Bernstein | Outperform | Market Perform | -- | $130 | Jan. 10, 2025 |
| Upgrade | RVTY | BofA Securities | Neutral | Buy | -- | $138 | Dec. 13, 2024 |
| Upgrade | RVTY | Barclays | Equal Weight | Overweight | $125 | $140 | Oct. 15, 2024 |
| Initiation | RVTY | Wells Fargo | -- | Equal Weight | -- | $130 | Aug. 28, 2024 |
News
RVTY Stock Falls Despite the Latest Launch of Automated Instrument
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.
Read More
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. The highly versatile IDS i20 in.
Read More
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Negative
Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the company maintained full-year guidance. While I rate Revvity a buy, it faces some structural challenges longer-term.
Read More
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Read More
Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript
Published: April 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Revvity, Inc. (NYSE:RVTY ) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Catherine Schulte - Baird Daniel Arias - Stifel Dan Leonard - UBS Luke Sergott - Barclays Tycho Peterson - Jefferies Operator Welcome everyone to Q1 2025 Revvity Earnings Conference Call. My name is Sammy, and …
Read More
Revvity beats quarterly estimates on steady demand for medical equipment
Published: April 28, 2025 by: Reuters
Sentiment: Positive
Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, helped by steady demand from biotech clients for medical equipment used for drug research.
Read More
Why Revvity (RVTY) Could Beat Earnings Estimates Again
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
Read More
Revvity Stock Tumbles Despite Expanding Genomics England Alliance
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes.
Read More
About Revvity, Inc. (RVTY)
- IPO Date 1965-07-06
- Website https://www.perkinelmer.com
- Industry Medical - Diagnostics & Research
- CEO Dr. Prahlad R. Singh Ph.D.
- Employees 11000